Let's Only Sell High-Growth Drugs

GlaxoSmithKline (NYSE: GSK  ) and "high growth" haven't typically gone hand in hand. Revenue at the pharma giant has grown by an average of just 3.5% over the last five years. But Glaxo has a plan to change that: sell off the stuff that isn't growing.

Sounds good, in theory.

Glaxo sold off an eclectic group of over-the-counter medications in a series of transactions. And today it announced the divestiture of 25 "classic brands" of prescription drugs in Australia to Aspen Global. "Classic brands" is a euphemism for drugs that aren't selling well anymore, mostly because they have generic competition. The drugs, which include Valtrex, Lamictal, Timentin, Amoxil, and Aropax, are on pace for a 25% decline this year.

Getting the drugs off the books -- and picking up around $270 million in the process -- will help the year-over-year revenue comparison. It'll hurt the profit line, but probably not by much since these are likely low-margin products.

Pfizer (NYSE: PFE  ) has taken the opposite approach, choosing to hold onto its older drugs, which it fondly refers to as "established products." The company even added to its portfolio a few years ago. Novartis (NYSE: NVS  ) has a whole division, called Sandoz, to develop and sell generics and Sanofi (NYSE: SNY  ) moved onto the international generic scene with a series of purchases a few years ago.

Which is the better strategy? Dabbling in generics doesn't make a whole lot of sense; volume is key to making a low-margin business work. But it's not like they're hurting anything unless you really believe the drugs are distracting, then I guess selling them off makes most sense. In the bigger picture, I don't think it really matters all that much. Growth will come from launching new drugs that sell well. Plain and simple.

It seems to me that concentrating on how it's going to develop high-growth drugs should be a higher priority for Glaxo than selling off two dozen low-growth ones.

Dividends can help investors ride the waves of slow drug development times. Check out the Fool's free report "Secure Your Future With 9 Rock-Solid Dividend Stocks" where you'll find one drug developer and eight other promising companies. Just click here to get your free copy.

Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool has a disclosure policy.

We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 1986680, ~/Articles/ArticleHandler.aspx, 4/16/2014 3:02:39 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement